Holen Sie sich die Stockscreener-App
8.91
1.76%
-0.16
Handel nachbörslich:
8.94
0.03
+0.34%
Schlusskurs vom Vortag:
$9.07
Offen:
$9.01
24-Stunden-Volumen:
989.31K
Relative Volume:
1.10
Marktkapitalisierung:
$681.78M
Einnahmen:
$31,000
Nettoeinkommen (Verlust:
$-54.42M
KGV:
-9.1123
EPS:
-0.9778
Netto-Cashflow:
$-48.99M
1W Leistung:
-7.76%
1M Leistung:
-19.87%
6M Leistung:
+73.01%
1J Leistung:
+49.12%
1-Tages-Spanne:
$8.79
$9.0999
1-Wochen-Bereich:
$8.79
$10.18
52-Wochen-Spanne:
$4.35
$14.00
Candel Therapeutics Inc Stock (CADL) Company Profile
Firmenname
Candel Therapeutics Inc
Sektor
Branche
Telefon
617-916-5445
Adresse
117 KENDRICK STREET, NEEDHAM
Compare CADL vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
8.91 | 681.78M | 31,000 | -54.42M | -48.99M | -0.9778 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-21 | Hochstufung | BofA Securities | Neutral → Buy |
| 2026-07-13 | Eingeleitet | Stifel | Buy |
| 2026-04-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-10-28 | Eingeleitet | Stephens | Overweight |
| 2025-09-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-06-30 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-20 | Eingeleitet | Citigroup | Buy |
| 2025-02-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-02-07 | Eingeleitet | BofA Securities | Buy |
| 2022-12-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-08-23 | Eingeleitet | Credit Suisse | Outperform |
| 2021-08-23 | Eingeleitet | Jefferies | Buy |
| 2021-08-23 | Eingeleitet | UBS | Buy |
Alle ansehen
Candel Therapeutics Inc Aktie (CADL) Neueste Nachrichten
A director receives 2,189 options instead of quarterly cash pay at Candel Therapeutics (CADL). - Stock Titan
Candel Therapeutics to Present at the SITC 2026 Annual Meeting - GlobeNewswire Inc.
Form 4 Candel Therapeutics Inc For: 2 October By Investing.com - Investing.com Nigeria
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo! Finance Canada
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
CADL Slides As Form 144 Filing Flags Insider Selling Risk - timothysykes.com
Candel Therapeutics CEO Tak sells $3.16m in CADL stock By Investing.com - Investing.com Australia
Candel Therapeutics CEO Tak sells $3.16m in CADL stock By Investing.com - Investing.com South Africa
Candel Therapeutics CEO Tak sells $3.16m in CADL stock By Investing.com - Investing.com India
Candel Therapeutics (NASDAQ: CADL) CEO sells 280K shares under preset plan - Stock Titan
Candel Therapeutics (NASDAQ: CADL) investor plans $3.4M Rule 144 stock sale from equity awards - Stock Titan
Candel Therapeutics at Cantor global healthcare conference: prostate cancer push - Investing.com India
Candel (CADL) gives director options with 36-month vesting - Stock Titan
Candel Therapeutics at Cantor global healthcare conference: prostate cancer push - Investing.com Canada
Candel Therapeutics, Inc. Announces Appointment of Martine Zimmermann to Board of Directors, Effective September 8, 2026 - marketscreener.com
Candel Therapeutics Adds Regulatory Veteran to Board Ahead of Q4 2026 BLA Submission - Minichart
Candel Therapeutics Adds Martine Zimmermann to Board Ahead of Planned BLA Filing - citybiz
Candel Therapeutics appoints Martine Zimmermann to board By Investing.com - Investing.com Canada
Candel Therapeutics appoints Martine Zimmermann to board - investing.com
Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors - The Manila Times
Candel Therapeutics appoints Martine Zimmermann to board By Investing.com - Investing.com UK
Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors - Yahoo Finance
Candel Therapeutics appoints Martine Zimmermann to board By Investing.com - Investing.com Nigeria
BB: BlackBerry Ltd Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
(CADL) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Candel Therapeutics Stock Price Forecast. Should You Buy CADL? - StockInvest.us
CADL 8-K FilingsCandel Therapeutics, Inc. SEC 8-K - Stock Titan
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Show Me The Money: CADL Delivers 190%+ Gain In Less Than Six Months As BLA Filing Nears - RTTNews
Candel Therapeutics stock hits 52-week high at $13.96 By Investing.com - Investing.com South Africa
Candel Therapeutics stock hits 52-week high at $13.96 By Investing.com - Investing.com Canada
Candel Therapeutics stock hits 52-week high at $13.96 - investing.com
Candel Therapeutics stock hits 52-week high at $13.96 By Investing.com - Investing.com UK
Oncolytic Virus Cancer Therapy Market Expected to Expand Rapidly During the Forecast Period (2026-2036) Amid Rising Investments in Next-Generation Cancer Treatments| DelveInsight - PR Newswire UK
Candel Therapeutics to Present at September Investor Conferences - The Manila Times
Candel Therapeutics (CADL) Is Up 5.4% After Steep Q2 Loss Widening Has The Bull Case Changed? - Yahoo Finance
Analysts Issue Forecasts for CADL FY2026 Earnings - MarketBeat
Candel Therapeutics, Inc. (CADL) Stock Price, News, Quote & History - Yahoo Finance
Candel Therapeutics (CADL) Faces Bigger Losses As Its Valuation Still Looks Pricey - Yahoo Finance
Candel Therapeutics (CADL) Is Up 26.4% After Swinging Back to Losses in Q2 2026 – Has The Bull Case Changed? - simplywall.st
Candel Therapeutics (CADL) Is Up 26.4% After Swinging Back to Losses in Q2 2026 – Has The Bull Case Changed? - simplywall.st
Candel Therapeutics (NASDAQ:CADL) CTO Seshu Tyagarajan Sells 7,000 Shares of Stock - MarketBeat
Candel Therapeutics (CADL) CTO sells 7,000 shares via 10b5-1 plan - Stock Titan
Candel Therapeutics (NASDAQ:CADL) Hits New 1-Year HighHere's Why - MarketBeat
Candel Therapeutics CTO Seshu Tyagarajan Executes 7,000-Share Sale Under 10b5-1 Plan - Kalkine Media
Candel Therapeutics (NASDAQ: CADL) insider plans 7,000-share 10b5-1 sale - Stock Titan
Candel Therapeutics (NASDAQ:CADL) Trading 6.4% Higher Following Analyst Upgrade - MarketBeat
Freedom Broker raises Candel Therapeutics stock price target on trial progress - Investing.com Canada
Finanzdaten der Candel Therapeutics Inc-Aktie (CADL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Candel Therapeutics Inc-Aktie (CADL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Tak Paul Peter | Chief Executive Officer |
Sep 11 '26 |
Sale |
10.46 |
59,379 |
620,891 |
113,321 |
| Tak Paul Peter | Chief Executive Officer |
Sep 10 '26 |
Sale |
11.50 |
220,866 |
2,539,893 |
172,700 |
| PAUL PETER TAK | Director |
Sep 10 '26 |
Proposed Sale |
12.17 |
280,245 |
3,410,582 |
0 |
| Tyagarajan Seshu | Chief Technology Officer |
Aug 17 '26 |
Sale |
12.00 |
7,000 |
84,000 |
76,865 |
| SESHU TYAGARAJAN | Officer |
Aug 17 '26 |
Proposed Sale |
11.72 |
7,000 |
82,040 |
0 |
| Barone Francesca | Chief Scientific Officer |
Jun 29 '26 |
Sale |
10.06 |
23,447 |
235,769 |
77,362 |
| Tyagarajan Seshu | Chief Technology Officer |
Jun 29 '26 |
Sale |
10.02 |
7,000 |
70,151 |
83,865 |
| SESHU P TYAGARAJAN | Officer |
Jun 29 '26 |
Proposed Sale |
9.79 |
7,000 |
68,530 |
0 |
| FRANCESCA BARONE | Officer |
Jun 29 '26 |
Proposed Sale |
9.79 |
23,447 |
229,546 |
0 |
| Manning Paul B | Director |
Feb 23 '26 |
Buy |
5.45 |
550,458 |
2,999,996 |
2,763,527 |
1.91%
3.96%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):